高级检索
当前位置: 首页 > 详情页

KDM2A plays a dual role in regulating the expression of malignancy-related genes in esophageal squamous cell carcinoma

文献详情

资源类型:
Pubmed体系:
机构: [1]Experimental Medicine Center, The Affiliated Hospital of Southwest Medical University, Luzhou Key Laboratory of Molecular Cancer, Luzhou, 646000, China [2]Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, 646000, PR China [3]Institute of Integrated Chinese and Western Medicine, National Traditional Chinese Medicine Clinical Research Base of the Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, 646000, China
出处:
ISSN:

关键词: KDM2A Proliferation Migration Esophageal squamous cell carcinoma Oncogenes Histone marks

摘要:
KDM2A is a histone demethylase, which primarily catalyzes the demethylation of H3K36me2. Abnormal expression of KDM2A is observed in many types of cancers; however, the molecular events connected to KDM2A expression remain unclear. We report that KDM2A performs an oncogenic function in esophageal squamous cell carcinoma (ESCC) and is robustly expressed in ESCC cells. ShRNA-mediated knockdown of KDM2A resulted in a significant inhibition of the malignant phenotype of ESCC cell lines, whereas ectopic expression of KDM2A showed the opposite effect. We also analyzed the function of KDM2A using a CRISPR-CAS9 depletion system and subsequent rescue experiment, which also indicated a cancerous role of KDM2A. Interestingly, analysis of the gene expression network controlled by KDM2A using RNA-seq revealed an unexpected feature: KDM2A could induce expression of a set of well-documented oncogenic genes, including IL6 and LAT2, while simultaneously suppressing another set of oncogenes, including MAT2A and HMGCS1. Targeted inhibition of the upregulated oncogene in the KDM2A-depleted cells led to a synergistic suppressive effect on the malignant phenotype of ESCC cells. Our results revealed the dual role of KDM2A in ESCC cells, which may have therapeutic implications.Copyright © 2022 Elsevier Inc. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 4 区 生物学
小类 | 4 区 生化与分子生物学 4 区 生物物理
最新[2023]版:
大类 | 3 区 生物学
小类 | 3 区 生物物理 4 区 生化与分子生物学
第一作者:
第一作者机构: [1]Experimental Medicine Center, The Affiliated Hospital of Southwest Medical University, Luzhou Key Laboratory of Molecular Cancer, Luzhou, 646000, China
共同第一作者:
通讯作者:
通讯机构: [1]Experimental Medicine Center, The Affiliated Hospital of Southwest Medical University, Luzhou Key Laboratory of Molecular Cancer, Luzhou, 646000, China [2]Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, 646000, PR China [3]Institute of Integrated Chinese and Western Medicine, National Traditional Chinese Medicine Clinical Research Base of the Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, 646000, China [*1]Experimental Medicine Center, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Luzhou, 646000, Sichuan, China. [*2]Experimental Medicine Center, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Luzhou, 646000, Sichuan, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:54051 今日访问量:1 总访问量:4615 更新日期:2025-03-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号